Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2025Magnificent 7Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary Marketplace / Trade Private Companies / Buy and Sell Acelyrin Stock
Acelyrin

Acelyrin Stock

$809.52MM
Series C Valuation, Sep 2022
Register To Buy and Sell Private Company Shares
For more details on private stock price information, financing and valuation for Acelyrin, register or login.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Acelyrin Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Acelyrin Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/09/2022 Series C $300MM $xx.xx $809.52MM Access Biotechnology, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, Matrix Capital Management, Orbimed, Samsara Biocapital, Surveyor Capital, Tybourne Capital Management, Venbio Partners, Westlake Village Biopartners
Price per Share
$xx.xx
Shares Outstanding
48,230,736
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Access Biotechnology, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, Matrix Capital Management, Orbimed, Samsara Biocapital, Surveyor Capital, Tybourne Capital Management, Venbio Partners, Westlake Village Biopartners
11/16/2021 Series B $250MM $xx.xx $364.33MM Cowen Healthcare Investments, Decheng Capital, Marshall Wace, Matrix Capital Management, Orbimed, Samsara Biocapital, Surveyor Capital, Tybourne Capital Management, Venbio Partners, Westlake Village Biopartners
Price per Share
$xx.xx
Shares Outstanding
48,230,900
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cowen Healthcare Investments, Decheng Capital, Marshall Wace, Matrix Capital Management, Orbimed, Samsara Biocapital, Surveyor Capital, Tybourne Capital Management, Venbio Partners, Westlake Village Biopartners
12/15/2020 Series A $8MM $xx.xx $14.55MM Westlake Village Biopartners
Price per Share
$xx.xx
Shares Outstanding
8,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Westlake Village Biopartners
Company Details
Acelyrin is a biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines. Acelyrin partners with big pharmaceutical companies, early-stage startups, and academia with a blend of scientific, medical, operational, and company-building experience to bring its treatments and therapeutics to the public, and transform patient's lives through healing and well-being. Acelyrin was founded in 2020 by Robert Carey and is headquartered in Agoura Hills, CA.
Founded
2020
Headquarters
Agoura Hills, CA, United States
Post-Money Valuation 3
$809.52MM
Total Funding
$558MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C

Acelyrin Stock FAQs

To buy and sell Acelyrin stock
Can you buy Acelyrin stock?
As Acelyrin is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Acelyrin, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Acelyrin stock?

To invest in a private company like Acelyrin through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Acelyrin stock?
Yes, you may sell the Acelyrin stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Acelyrin stock?

If you hold private company shares of Acelyrin – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Acelyrin on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Acelyrin stock
Is Acelyrin a public company?
No, Acelyrin is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Acelyrin’s stock price?
Acelyrin is a privately held company and therefore does not have a public stock price. However, you may access Acelyrin private market stock price with Forge Data.
What is Acelyrin’s stock ticker symbol?
Acelyrin does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Acelyrin Investors Also Invested in These Private Companies

Tybourne Capital Management
Orbimed Healthcare Fund Management
Westlake Village Biopartners

Leadership & Board

Leadership

Shao-Lee Lin, MD, PhD
Chief Executive Officer
Robert F. Carey
President
Paul Peloso
Chief Medical Officer
Melanie Gloria
Chief Operating Officer
Gil Labrucherie
Chief Financial Officer
Ron Oyston
Senior Vice President, Human Resources
Marc Kubasak
Vice President, Program Lead & Regulatory Affairs
Brian Wiens
Vice President, Biostatistics and Data Sciences
Terry Bevirt
Vice President, Alliance Management, Clinical & Corporate Quality
Katherine To
Vice President - Clinical Operations
Suzy Buckhalter
Senior Director, Finance & Accounting
Tyler Marciniak
Head of Investor Relations and Communications
Shawn Eisnberg
Vice President, Technical Operations

Board

Sean Harper
Kin Insurance
Alan Colowick
Sofinnova Investments
Beth Seidenberg
Westlake Village BioPartners
Dan Becker
Access Biotechnology
Richard Gaster
venBio Partners

Acelyrin News and Media Highlights

Immunology-Drug Startup Acelyrin Raises $300 Million for Late-Stage Trials

Drugmaker Acelyrin has raised $300 million in new venture capital to run late-stage clinical trials of a drug that could treat certain forms of arthritis and other conditions and compete with top-selling medications.
Browse Insights
Other Companies Like Acelyrin in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
EgenesisEgenesis----$xx.xxSeries D$332.59MM$xx.xx$90.96MM
Eikon TherapeuticsEikon Therapeutics----$xx.xxSeries D$1.45B$xx.xx$400MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
Kailera TherapeuticsKailera Therapeutics----$xx.xxSeries A-2 NV$580.71MM$xx.xx$7.09MM
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
Mammoth BiosciencesMammoth Biosciences----$xx.xxSeries D-2$1.35B$xx.xx$107.74MM
OriginOrigin----$xx.xx--------

Updated on: Mar 8, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.